LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway

For patients exhibiting non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a first-line treatment. However, most patients who initially responded to EGFR-TKIs eventually dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Chunsheng, Zhou, Anting, Hu, Xin, Xiang, Yu, Huang, Mengjun, Huang, Jiuhong, Yang, Donglin, Tang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658955/
https://www.ncbi.nlm.nih.gov/pubmed/36362025
http://dx.doi.org/10.3390/ijms232113237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658955/
https://www.ncbi.nlm.nih.gov/pubmed/36362025
http://dx.doi.org/10.3390/ijms232113237

Ejemplares similares